SCHEMBL1082437

SCHEMBL1082437

O=C(NO)c1ccc2c(c1)CCN(C(=O)OCc1ccccc1)C2

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TMEM97 Q5BJF2 11/20 0.64
SIGMAR1 Q99720 11/20 0.64
HDAC6 Q9UBN7 9/20 0.57
HDAC1 Q13547 3/20 0.57
HDAC8 Q9BY41 2/20 0.56
HDAC10 Q969S8 1/20 0.55
HTR1A P08908 2/20 0.53
ADRA2A P08913 2/20 0.53
ADRA2B P18089 2/20 0.53
HRH2 P25021 2/20 0.53
HTR2A P28223 2/20 0.53
HTR2C P28335 2/20 0.53
HRH1 P35367 2/20 0.53
HTR2B P41595 2/20 0.53
HRH3 Q9Y5N1 2/20 0.53
ADRA2C P18825 1/20 0.53
DRD1 P21728 1/20 0.53
HTR1B P28222 1/20 0.53
HTR1E P28566 1/20 0.53
SLC6A4 P31645 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1027550 0.90 TMEM97 (0.67) TMEM97SIGMAR1HTR1AADRA2AADRA2B
SCHEMBL2277280 0.88 TMEM97 (0.66) TMEM97SIGMAR1HTR1AADRA2AADRA2B
SCHEMBL31173403 0.87 TMEM97 (0.68) TMEM97SIGMAR1HTR1AADRA2AADRA2B
SCHEMBL18530311 0.85 TMEM97 (0.67) TMEM97SIGMAR1HTR1AADRA2AADRA2B
SCHEMBL30031624 0.85 TMEM97 (0.67) TMEM97SIGMAR1HTR1AADRA2AADRA2B
SCHEMBL1793928 0.85 TMEM97 (0.67) TMEM97SIGMAR1HTR1AADRA2AADRA2B
SCHEMBL3187484 0.84 TMEM97 (0.70) TMEM97SIGMAR1HTR1AADRA2AADRA2B
SCHEMBL30645345 0.84 TMEM97 (0.70) TMEM97SIGMAR1HTR1AADRA2AADRA2B
SCHEMBL8463640 0.83 TMEM97 (0.66) TMEM97SIGMAR1HTR1AADRA2AADRA2B
SCHEMBL324228 0.83 TMEM97 (0.67) TMEM97SIGMAR1HTR1AADRA2AADRA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8575193-B2 N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds 4SC AG (DE) 2013-11-05 US claimed
US-20110201643-A1 NOVEL N-SUBSTITUTED TETRAHYDROISOQUINOLINE/ISOINDOLINE HYDROXAMIC ACID COMPOUNDS 4SC AG (DE) 2011-08-18 US claimed
EP-2100879-A1 Novel N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds 4SC AG (DE) 2009-09-16 EP claimed
US-8575193-B2 N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds 4SC AG (DE) 2013-11-05 US disclosed
US-20110201643-A1 NOVEL N-SUBSTITUTED TETRAHYDROISOQUINOLINE/ISOINDOLINE HYDROXAMIC ACID COMPOUNDS 4SC AG (DE) 2011-08-18 US disclosed
EP-2274283-A1 NOVEL N-SUBSTITUTED TETRAHYDROISOQUINOLINE/ISOINDOLINE HYDROXAMIC ACID COMPOUNDS 4SC AG (DE) 2011-01-19 EP disclosed
WO-2009112550-A1 NOVEL N-SUBSTITUTED TETRAHYDROISOQUINOLINE/ISOINDOLINE HYDROXAMIC ACID COMPOUNDS 4SC AG (DE) 2009-09-17 WO disclosed
EP-2100879-A1 Novel N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds 4SC AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201643-A1 NOVEL N-SUBSTITUTED TETRAHYDROISOQUINOLINE/ISOINDOLINE HYDROXAMIC ACID COMPOUNDS HDAC1, HDAC3, HDAC4 TMEM97 3168/4885SIGMAR1 1674/4885HDAC6 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.